Gsk (GLAXF) Research & Development (2009 - 2026)

Gsk's Research & Development history runs 18 years deep, the most recent figure standing at -$2.3 billion for Q1 2026.

• In Q1 2026, Research & Development fell 23.88% year-over-year to -$2.3 billion; the TTM figure through Mar 2026 stood at -$17.3 billion (down 24.99% YoY), while the FY2025 annual figure was $9.9 billion, up 21.26% from the prior year.
• Research & Development was -$2.3 billion for Q1 2026 at Gsk, up from -$10.0 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$1.5 billion in Q1 2022 to a low of -$10.0 billion in Q4 2025.
• Historically, Research & Development has averaged -$3.3 billion across 5 years, with a median of -$1.9 billion in 2024.
• Biggest YoY gain for Research & Development was 18.74% in 2022; the steepest drop was 247.04% in 2022.
• A 5-year view of Research & Development shows it stood at -$6.4 billion in 2022, then decreased by 19.99% to -$7.7 billion in 2023, then declined by 6.37% to -$8.2 billion in 2024, then dropped by 21.83% to -$10.0 billion in 2025, then soared by 77.21% to -$2.3 billion in 2026.
• The last three Research & Development figures came in at -$2.3 billion (Q1 2026), -$10.0 billion (Q4 2025), and -$2.3 billion (Q3 2025), per Business Quant data.